Stephen Hanauer to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Stephen Hanauer has written about Tumor Necrosis Factor-alpha.
Connection Strength
4.194
-
The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease. Expert Rev Gastroenterol Hepatol. 2025 Jul; 19(7):725-743.
Score: 0.717
-
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5.
Score: 0.321
-
Still in pursuit. Gastroenterology. 2014 Jan; 146(1):13-5.
Score: 0.321
-
Commentary: pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012 Jul; 36(2):199-200; discussion 200.
Score: 0.291
-
Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis. 2011 Nov; 17(11):2366-91.
Score: 0.265
-
Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48.
Score: 0.235
-
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
Score: 0.161
-
Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7.
Score: 0.152
-
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33.
Score: 0.117
-
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
Score: 0.107
-
Targeting Crohn's disease. Lancet. 2017 12 23; 390(10114):2742-2744.
Score: 0.105
-
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34.
Score: 0.092
-
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3.
Score: 0.083
-
Comparing guidelines for the treatment of inflammatory bowel disease. Dig Dis. 2013; 31(3-4):360-2.
Score: 0.080
-
Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18.
Score: 0.067
-
The role of biologics in ulcerative colitis. Dig Dis. 2010; 28(3):497-500.
Score: 0.064
-
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
Score: 0.059
-
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68.
Score: 0.053
-
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
Score: 0.052
-
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
Score: 0.052
-
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38.
Score: 0.051
-
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22.
Score: 0.050
-
General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
Score: 0.049
-
The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):59.
Score: 0.047
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
Score: 0.047
-
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76.
Score: 0.046
-
Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493.
Score: 0.046
-
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.
Score: 0.044
-
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
Score: 0.043
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
Score: 0.040
-
Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
Score: 0.039
-
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94.
Score: 0.035
-
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8.
Score: 0.034
-
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
Score: 0.030
-
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct; 117(4):761-9.
Score: 0.030
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35.
Score: 0.026
-
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
Score: 0.024
-
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40.
Score: 0.022
-
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
Score: 0.017
-
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51.
Score: 0.017
-
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
Score: 0.017
-
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7.
Score: 0.016
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
Score: 0.016
-
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36.
Score: 0.015